99.40 +0.01 (0.01%)
After hours: 4:45PM EST
|Bid||96.82 x 900|
|Ask||102.46 x 1000|
|Day's range||98.28 - 101.22|
|52-week range||62.48 - 110.37|
|Beta (5Y monthly)||0.96|
|PE ratio (TTM)||N/A|
|Earnings date||09 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||105.69|
Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Squamous Cell Carcinoma of the Anal Canal (SCAC)
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 9, 2021.